Treatment for Insomnia in Adults Taking Adderall for ADHD

Introduction to CBT-I and Adderall Optimization

The American College of Physicians recommends starting with Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for adults with chronic insomnia, including those taking stimulants for ADHD, due to its superior long-term outcomes and minimal adverse effects 1, 2, 3
CBT-I must be the initial intervention for all adults with chronic insomnia, including those taking stimulants for ADHD, and provides superior long-term outcomes compared to medications 1, 2, 3

Stimulus control therapy, which associates the bed only with sleep and involves leaving the bedroom if unable to sleep within 20 minutes, is a key component of CBT-I 4, 3
Sleep restriction therapy, limiting time in bed to actual sleep time and gradually increasing it as sleep efficiency improves, is another crucial component of CBT-I 4, 3
Cognitive restructuring to address maladaptive thoughts about sleep and anxiety related to insomnia is an essential part of CBT-I 3
Sleep hygiene optimization, including avoiding caffeine after early afternoon, eliminating evening alcohol, avoiding late exercise, and optimizing the sleep environment, is vital for effective CBT-I 4

The American Academy of Sleep Medicine recommends ramelteon 8 mg, zaleplon 10 mg, or zolpidem 10 mg (5 mg if elderly) as first-line pharmacological options for sleep onset insomnia in adults taking Adderall for ADHD 4
For sleep maintenance insomnia, low-dose doxepin 3-6 mg, eszopiclone 2-3 mg, or suvorexant are recommended pharmacological options, with doxepin reducing wake after sleep onset by 22-23 minutes 4

The American Academy of Sleep Medicine specifically recommends avoiding benzodiazepines in patients with substance use history, including those taking stimulants for ADHD, due to compounded abuse potential and cognitive effects 3, 4
Over-the-counter antihistamines (diphenhydramine) should not be used due to lack of efficacy data and problematic daytime sedation and cognitive impairment 4, 5
Pharmacotherapy should be prescribed at the lowest effective dose for the shortest duration (4-5 weeks maximum initially) to minimize risks, including daytime impairment, complex sleep behaviors, falls, fractures, and potential cognitive changes 1, 2, 4